MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients

Leonhard Gruber; Luis David Jiménez-Franco; Clemens Decristoforo; Christian Uprimny; Gerhard Glatting; Peter Hohenberger; Stefan O. Schoenberg; Wolfgang Reindl; Francesca Orlandi; Maurizio Mariani; Werner Jaschke; Irene Virgolini

doi:10.2967/jnumed.119.238808

Research ArticleOncology

MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of ⁶⁸Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients

Leonhard Gruber, Luis David Jiménez-Franco, Clemens Decristoforo, Christian Uprimny, Gerhard Glatting, Peter Hohenberger, Stefan O. Schoenberg, Wolfgang Reindl, Francesca Orlandi, Maurizio Mariani, Werner Jaschke and Irene Virgolini

Journal of Nuclear Medicine December 2020, 61 (12) 1749-1755; DOI: https://doi.org/10.2967/jnumed.119.238808

Leonhard Gruber

1Department of Radiology, Medical University Innsbruck, Innsbruck, Austria

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Luis David Jiménez-Franco

2Medical Radiation Physics/Radiation Protection, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Clemens Decristoforo

3Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christian Uprimny

3Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Gerhard Glatting

2Medical Radiation Physics/Radiation Protection, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

4Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Peter Hohenberger

5Division of Surgical Oncology and Thoracic Surgery, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Stefan O. Schoenberg

6Institute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Wolfgang Reindl

7Klinikum Mannheim II, Medizinische Klinik, Mannheim, Germany; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Francesca Orlandi

8Advanced Accelerator Applications, a Novartis Company, Colleretto Giacosa TO, Italy

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Maurizio Mariani

8Advanced Accelerator Applications, a Novartis Company, Colleretto Giacosa TO, Italy

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Werner Jaschke

1Department of Radiology, Medical University Innsbruck, Innsbruck, Austria

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Irene Virgolini

3Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 61, Issue 12

December 1, 2020

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of ⁶⁸Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients

Journal of Nuclear Medicine Dec 2020, 61 (12) 1749-1755; DOI: 10.2967/jnumed.119.238808

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of ⁶⁸Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients

Journal of Nuclear Medicine Dec 2020, 61 (12) 1749-1755; DOI: 10.2967/jnumed.119.238808

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

This Month in JNM

PubMed
Google Scholar

Cited By...

Safety, Biodistribution, and Radiation Dosimetry of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors
Head-to-Head Comparison of [68Ga]Ga-NOTA-RM26 and [18F]FDG PET/CT in Patients with Gastrointestinal Stromal Tumors: A Prospective Study
Prospective Comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer

Google Scholar

Oncology

Comparative PSMA expression at early (1hour) vs late (2hour) in primary and secondary sites of involvement in prostate cancer.
Imaging spectrum of peritoneal carcinomatosis associated with various etiologies on 18F-FDG PET/CT
Hybrid Imaging Features of Musculoskeletal Tumors

Show more Oncology

Clinical

Addition of ¹³¹I-MIBG to PRRT (⁹⁰Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
SUVs Are Adequate Measures of Lesional ¹⁸F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden
Hypermetabolism on Pediatric PET Scans of Brain Glucose Metabolism: What Does It Signify?

Show more Clinical

Keywords

GIST
PET
68Ga-NeoBOMB1
GRPR
Phase I/IIa study

Main menu

User menu

Search

MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of ⁶⁸Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Oncology

Clinical

Similar Articles

Keywords